Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials.
Publication
, Journal Article
Klintmalm, GB; Vincenti, F; Kirk, A
Published in: Am J Transplant
November 2016
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Am J Transplant
DOI
EISSN
1600-6143
Publication Date
November 2016
Volume
16
Issue
11
Start / End Page
3077 / 3078
Location
United States
Related Subject Headings
- Surgery
- Kidney Transplantation
- Kidney
- Immunosuppressive Agents
- Immunosuppression Therapy
- Humans
- Graft Rejection
- Endpoint Determination
- Acute Disease
- Abatacept
Citation
APA
Chicago
ICMJE
MLA
NLM
Klintmalm, G. B., Vincenti, F., & Kirk, A. (2016). Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials. Am J Transplant, 16(11), 3077–3078. https://doi.org/10.1111/ajt.13889
Klintmalm, G. B., F. Vincenti, and A. Kirk. “Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials.” Am J Transplant 16, no. 11 (November 2016): 3077–78. https://doi.org/10.1111/ajt.13889.
Klintmalm GB, Vincenti F, Kirk A. Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials. Am J Transplant. 2016 Nov;16(11):3077–8.
Klintmalm, G. B., et al. “Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials.” Am J Transplant, vol. 16, no. 11, Nov. 2016, pp. 3077–78. Pubmed, doi:10.1111/ajt.13889.
Klintmalm GB, Vincenti F, Kirk A. Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials. Am J Transplant. 2016 Nov;16(11):3077–3078.
Published In
Am J Transplant
DOI
EISSN
1600-6143
Publication Date
November 2016
Volume
16
Issue
11
Start / End Page
3077 / 3078
Location
United States
Related Subject Headings
- Surgery
- Kidney Transplantation
- Kidney
- Immunosuppressive Agents
- Immunosuppression Therapy
- Humans
- Graft Rejection
- Endpoint Determination
- Acute Disease
- Abatacept